ArticleOncogene2026
RNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Neddylation, a post-translational modification process involving three enzymatic steps, is crucial in regulating various cancers. However, its specific mechanisms in pancreatic cancer (PC) remain largely unexplored. This study focused on screening neddylation-related molecules in PC and identified RNF187 as a key player, demonstrating its overexpression in PC and its ability to enhance cell proliferation and invasion both in vitro and in vivo. Notably, NEDD8 could bind to RNF187, preventing its degradation via K48-linked ubiquitination. This interaction stabilized RNF187, leading to increased protein levels and subsequent stimulation of PC cell proliferation and invasion. However, this mechanism alone did not fully account for how RNF187 could exacerbate PC malignancy. Further research revealed that RNF187 upregulated IQGAP1 protein levels through modulation of K48- and K63-linked ubiquitination. This post-translational modification triggered the rearrangement of the actin cytoskeleton in PC cells by altering the transcriptional levels of MYH9, thereby promoting PC malignancy. Overall, our findings demonstrate that neddylation of RNF187 enhances PC malignancy through the IQGAP1/MYH9 axis, suggesting a new therapeutic target for PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.